uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Hyaluronan-CD44 interactions as potential targets for cancer therapy
Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm , Ludwig Institute for Cancer Research.
Department of Biomedical Engineering ⁄ ND20, Cleveland Clinic, Cleveland, OH, USA.
Department of Chemistry, Laboratory of Biochemistry, University of Patras, Greece.
Show others and affiliations
2011 (English)In: The FEBS Journal, ISSN 1742-464X, E-ISSN 1742-4658, Vol. 278, no 9, 1429-1443 p.Article, review/survey (Refereed) Published
Abstract [en]

It is becoming increasingly clear that signals generated in tumor microenvironments are crucial to tumor cell behavior, such as survival, progression and metastasis. The establishment of these malignant behaviors requires that tumor cells acquire novel adhesion and migration properties to detach from their original sites and to localize to distant organs. CD44, an adhesion/homing molecule, is a major receptor for the glycosaminoglycan hyaluronan, which is one of the major components of the tumor extracellular matrix. CD44, a multistructural and multifunctional molecule, detects changes in extracellular matrix components, and thus is well positioned to provide appropriate responses to changes in the microenvironment, i.e. engagement in cell-cell and cell-extracellular matrix interactions, cell trafficking, lymph node homing and the presentation of growth factors/cytokines/chemokines to co-ordinate signaling events that enable the cell responses that change in the tissue environment. The potential involvement of CD44 variants (CD44v), especially CD44v4-v7 and CD44v6-v9, in tumor progression has been confirmed for many tumor types in numerous clinical studies. The downregulation of the standard CD44 isoform (CD44s) in colon cancer is postulated to result in increased tumorigenicity. CD44v-specific functions could be caused by their higher binding affinity than CD44s for hyaluronan. Alternatively, CD44v-specific functions could be caused by differences in associating molecules, which may bind selectively to the CD44v exon. This minireview summarizes how the interaction between hyaluronan and CD44v can serve as a potential target for cancer therapy, in particular how silencing CD44v can target multiple metastatic tumors.

Place, publisher, year, edition, pages
2011. Vol. 278, no 9, 1429-1443 p.
Keyword [en]
Cancer, CD44-varient, gene-therapy, hyaluronan, nanoparticles, stem cells, shRNA-therapy, tumorigenesis, tumor-stroma, wound-healing
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-152904DOI: 10.1111/j.1742-4658.2011.08071.xISI: 000289627800008PubMedID: 21362138OAI: oai:DiVA.org:uu-152904DiVA: diva2:414473
Available from: 2011-05-03 Created: 2011-05-03 Last updated: 2011-11-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Ludwig Institute for Cancer Research
In the same journal
The FEBS Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 162 hits
ReferencesLink to record
Permanent link

Direct link